Introduction {#Sec1}
============

Brain tumors are the most common solid tumors in children and constitute up to 20 % of childhood cancers \[[@CR1]\]. Significant breakthroughs in understanding the hallmarks of cancer biology, coupled with advances in diagnostic imaging and improved therapies, have enhanced the survival rates of these children \[[@CR2], [@CR3]\].

As the number of survivors of childhood brain tumors (SCBT) increased, it has become apparent that survivors remain at risk of premature mortality \[[@CR4]--[@CR6]\] and the development of multiple comorbidities \[[@CR7], [@CR8]\]. Many SCBT develop chronic health conditions within years of their initial diagnosis \[[@CR9]\], and one such morbidity is obesity \[[@CR10]--[@CR13]\]. In one study, obesity was reported in 36.5 % of SCBT, compared to 29 % in the general population \[[@CR14], [@CR15]\]. In the general population, the annual healthcare expenditures of obese individuals are about US\$1360 higher than for their non-obese counterparts \[[@CR16]\], and this is likely to be replicated in SCBT.

Addressing obesity in SCBT is crucial, as it increases the risk of cardiometabolic disorders in a similar fashion to the general population, and may contribute to premature mortality \[[@CR17], [@CR18]\]. Obesity is an independent risk factor for decreased survival in some children with brain tumors \[[@CR19]\]. Understanding the drivers of obesity in SCBT will allow the development of precision-based strategies for reducing the risk of obesity and its cardiometabolic comorbidities, which in turn may improve the quality of life and lifespan of SCBT.

Obesity in SCBT is multifactorial and can be related to altered energy intake \[[@CR20], [@CR21]\], reduced mobility and physical activity \[[@CR22]--[@CR25]\], hypothalamic-pituitary damage \[[@CR11]\], pituitary hormone deficiencies \[[@CR26]\], sleep problems \[[@CR27]\], vision problems, imbalance and pain \[[@CR8], [@CR28]\], mental health issues, and medications, e.g., antidepressants \[[@CR29]\].

As obese children are likely to become obese adults \[[@CR30]--[@CR34]\], it is important to develop effective interventions to manage obesity from an early age. The purpose of this systematic review is to evaluate current evidence of effectiveness of interventions to manage obesity in SCBT.

Research question {#Sec2}
-----------------

In survivors of childhood brain tumors, are the current interventions including lifestyle intervention, pharmacotherapy, and bariatric surgery effective in managing obesity?

Study objectives {#Sec3}
----------------

Measure the effectiveness of lifestyle interventions, pharmacotherapy, and bariatric surgery in the treatment of obesity in SCBTConduct a meta-analysis of primary studies, if appropriate, to gain a more precise estimate of the effectiveness of different strategies in managing obesityCritically appraise existing evidence and identify gaps in the literature to provide future research directions

Methods {#Sec4}
=======

The protocol for this systematic review is developed and reported with guidance from the Preferred Reporting Items for Systematic Review and Meta-Analysis-Protocols (PRISMA-P) statement (Additional file [1](#MOESM1){ref-type="media"}) \[[@CR35]\].

Eligibility criteria {#Sec5}
--------------------

This review will include studies involving boys and girls who are overweight or obese (BMI z-score ≥85th percentile) \[[@CR36]\], with a diagnosis of brain tumor made under the age of 18 years. Randomized controlled trials (RCTs), quasi-RCTs, prospective or retrospective cohort studies, case-control studies, cross-sectional studies, and controlled or uncontrolled studies with before-and-after comparisons will be included \[[@CR37]\].

There will be no restriction to the language or timing of publication. Conference proceedings, congress reports, and editorials will be hand searched for suggested relevant studies. We will exclude interim analyses, case reports, and pilot studies.

In studies where SCBT are included in an intervention with other cancer types, we will extract data for the brain tumor subgroup. If the data from subgroups are not published or pooled with data from survivors of other cancers, we will attempt to contact the authors to obtain the subgroup data.

The interventions included in the study areLifestyle intervention: any form of modifications in subjects' daily life including their dietary patterns, physical activity, and eating behaviorsPharmacotherapy: any administration of medicationsBariatric surgery: any surgical approach performed with the intention of treating obesity, including adjustable gastric banding, sleeve gastrectomy, biliopancreatic diversion with duodenal switch, and gastric bypass

Studies that are entered into the databases up to February 1, 2016, will be screened for eligibility. The search will be updated to capture recently published literature.

Outcome measures {#Sec6}
----------------

### Primary outcome {#Sec7}

The primary outcome in this review is BMI z-score change from baseline to the end of the intervention and/or at follow-up.

### Secondary outcomes {#Sec8}

Secondary outcomes include changes in waist and hip circumference, waist-to-hip ratio, waist-to-height ratio, body fat percentage, and blood pressure as reported. We will also report changes in diabetes status, insulin resistance, and non-alcoholic fatty liver disease, if available. In addition, we will document changes in lipid levels including high-density lipoprotein, low-density lipoprotein, cholesterol, and triglycerides, if reported.

We will also abstract any adverse events observed during the study. Adverse events directly related to lifestyle interventions include back and shoulder pain, musculoskeletal injuries, and others \[[@CR38], [@CR39]\]. Adverse events for the pharmacological agents include insomnia, headaches, hypertension, and others \[[@CR40]\]. Adverse outcomes for bariatric surgery include surgical complications, perioperative outcomes, and mortality as defined previously \[[@CR41]\]. Additional adverse events will be included as reported.

Search strategy {#Sec9}
---------------

We will consult a Health Sciences librarian with expertise in systematic reviews when designing the search strategy. A proposed search strategy for MEDLINE is described in Table [1](#Tab1){ref-type="table"}. Searches will be conducted in PubMed, MEDLINE, EMBASE, PsycINFO, SPORTDiscus, CINAHL, Cochrane Database of Systematic Review, Cochrane Central Register of Controlled Trials (CENTRAL), and Database of Abstracts of Reviews of Effect (DARE). We will search ClinicalTrials.gov and ProQuest Dissertations and Theses A&I to identify relevant gray literature. We will also search the reference lists of articles deemed eligible for inclusion in the analysis for relevant studies.Table 1Search strategy for MEDLINE1exp Child/2child\*.mp.3p?ediatric\*.mp.4exp Adolescent/5adolescen\*.mp.6youth\*.mp.7exp Adult/8adult\*.mp.9Young Adult/101 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 911exp Brain Neoplasms/12exp Cranial Nerve Neoplasms/13exp Neuroectodermal Tumors/14cerebroma\*.mp.15exp Glioma/16glioma\*.mp.17astrocytoma\*.mp.18oligoastrocytoma\*.mp.19astroglioma\*.mp.20glioblastoma\*.mp.21retinoblastoma\*.mp.22pinealoma\*.mp.23pineoblastoma\*.mp.24pinealoblastoma\*.mp.25pinealblastoma\*.mp.26pineal blastoma\*.mp.27pineocytoma\*.mp.28pinealocytoma\*.mp.29craniopharyngioma\*.mp.30ependymoma\*.mp.31subependymoma\*.mp.32ependymoblastoma\*.mp.33ganglioglioma\*.mp.34gliosarcoma\*.mp.35medulloblastoma\*.mp.36exp Germinoma/37germinoma\*.mp.38Meningioma/39meningioma\*.mp.40oligodendroglioma\*.mp.41exp Neurofibromatoses/42neurofibromatos\*.mp.43PNET\*.mp.44neurocytoma\*.mp.45choroid plexus papilloma\*.mp.46exp Neoplasms/47cancer\*.mp.48tumo?r\*.mp.49neoplasm\*.mp.5011 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 4951exp Obesity/52obes\*.mp.53Overweight/54over weight.mp.55overweight.mp.5651 or 52 or 53 or 54 or 5557life style\*.mp.58lifestyle\*.mp.59exp Diet/60diet\*.mp.61exp Nutrition Therapy/62nutrition.mp.63behavi\*.mp.64exp Exercise Therapy/65kinesiotherap\*.mp.66physical activ\*.mp.67exp Exercise/68exercis\*.mp.69walk\*.mp.70jog\*.mp.71run\*.mp.72swim\*.mp.73exp Bariatrics/74bariatric\*.mp.75bariatric surger\*.mp.76gastrojejunostomy.mp.77gastric bypass.mp.78stomach bypass.mp.79jejunoileal bypass.mp.80lipectomy.mp.81gastroplasty.mp.82stomach stapling.mp.83drug\*.mp.84pharm\*.mp.85exp Weight Reduction Programs/86((weight reduc\* or weight los\*) adj5 surger\*).mp.87((weight reduc\* or weight los\*) adj5 program\*).mp.8857 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 8789Body Weight/90body mass\*.mp.91BMI.mp.92exp Body Weight Changes/93exp Body Weights and Measures/94body fat.mp.95waist-height ratio\*.mp.96waist to height ratio\*.mp.97adipos\*.mp.98body size\*.mp.99waist circumference\*.mp.100hip circumference\*.mp.101weight\*.mp.102height\*.mp.103waist-hip ratio\*.mp.104waist to hip ratio\*.mp.105skinfold thickness\*.mp.10689 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 103 or 104 or 10510710 and 50 and 56 and 88 and 106

Data management {#Sec10}
---------------

Two independent reviewers will perform data abstraction and quality assessment. Disagreement between the two reviewers will be resolved by discussion, with subsequent involvement of a third reviewer to arbitrate disagreements. Excel spreadsheets will be used to manage study records during the screening process. We will use the Grading of Recommendations Assessment, Development and Evaluation Profiler (GRADEpro) software to create tables for summary of findings and quality assessment \[[@CR42]\].

Data screening {#Sec11}
--------------

Duplicates will be removed, followed by screening of titles and abstracts. Full-text articles that meet the inclusion criteria will be retrieved and screened. Screening at all steps will be conducted independently by two reviewers, who will meet after each step to ensure consistency and to resolve conflicts. In the case of persisting disagreement, a third reviewer will be consulted. A flow diagram will be included to report the screening process (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR43], [@CR44]\].Fig. 1Flow diagram of the article screening process

Data abstraction {#Sec12}
----------------

Data will be extracted independently by two reviewers, using a data abstraction form specifically designed for this systematic review. Details to be collected include title, authors, publication date, journal name, setting, country, funding source, study design, study duration, eligibility criteria, sample size, and methods used for brain tumor diagnosis including imaging, histology, and clinical assessment.

Participants' characteristics include age at diagnosis of brain tumor and at study enrollment, sex, ethnicity, and brain tumor location and laterality. Treatment details include radiotherapy type (fractionated or non-fractionated) and dose, chemotherapy type, dose and duration, and surgery details (total resection, partial resection, shunting, ventriculostomy, others).

Detailed description of the obesity interventions will be recorded including study design, components, duration, and adverse events. We will document primary and secondary outcomes of the studies. Adjustment for confounders and details of the statistical analyses performed will be extracted as well as study results. We will attempt to retrieve incomplete data by contacting the corresponding authors of published work.

Quality assessment {#Sec13}
------------------

The Risk of Bias Assessment Tool from the Cochrane Collaboration will be used to assess RCT \[[@CR45]\]. This tool includes six domains: sequence generation, allocation concealment, blinding, incomplete data, selective reporting outcomes, and other sources of bias. Each RCT will be rated as having either a high, low, or unclear risk of bias.

The Risk of Bias In Non-randomized Studies---of Interventions (ROBINS-I) assessment tool will be used for non-randomized studies such as cohort studies \[[@CR46]\]. This tool includes three domains: pre-intervention, at-intervention, and post-intervention.

In the pre-intervention domain, bias due to confounding and participant selection are evaluated. Possible confounding factors include brain tumor location, type, treatments, years of survival, age, sex, pubertal stage, baseline body composition, and presence of comorbidities such as metabolic syndrome and hormonal deficiency. Bias due to misclassification of the intervention status is assessed in the at-intervention domain. The post-intervention domain includes bias due to departures from the intended interventions, missing data, methods of outcome measurements, and selective reporting outcomes. In particular, co-interventions between lifestyle interventions, pharmacotherapy, and bariatric surgery can contribute to bias during the post-intervention domain. For example, participants may take antiobesity agents while they are on diet restriction. Each non-randomized study will be rated as having either a low, moderate, serious, critical, or unclear risk of bias.

The quality of uncontrolled studies will be assessed with a checklist developed by the University of Alberta Evidence-based Practice Center (UAEPC) \[[@CR47]\]. This checklist evaluates selection bias, incomplete data, and the methods of outcome assessments. We will tabulate risk of bias for all included studies and discuss its impact on the meta-analysis.

The quality of evidence will be assessed using the Grading quality of evidence and strength of recommendations (GRADE) guidelines \[[@CR48]\]. The GRADE guideline covers risk of bias, inconsistency, indirectness, imprecision, and publication bias. The overall quality of evidence is reported by each outcome measure as high, moderate, low, or very low.

Data analysis {#Sec14}
-------------

Detailed characteristics of the included studies will be provided, in addition to a meta-analysis if applicable. We will analyze each intervention separately, and outcomes will be analyzed separately based on study designs. We will perform a meta-analysis if two or more studies are identified per intervention.

Dichotomous outcomes will be reported as odds ratio, while continuous outcomes will be reported as standardized mean differences and 95 % confidence intervals. Expecting high levels of heterogeneity, our primary approach will emphasize the random effects estimate if more than ten studies can be identified \[[@CR49]\]. Otherwise, both random effect and fixed effect models will be presented.

Inconsistency index (*I*^2^) and *P* values will be used to quantify heterogeneity. The interpretation of the *I*^2^ will be based on the threshold set by the Cochrane Collaboration \[[@CR50]\]. If appropriate, a stratified analysis by sex will be pursued to identify a source of heterogeneity, as female SCBT are more at risk of developing obesity than males \[[@CR8], [@CR10]\].

If sufficient studies are identified for an outcome (≥10), we will perform sensitivity analysis by excluding outlier, small-sized, or highly biased studies to determine the impact of these studies on the meta-analysis result. To investigate publication bias, we will create a contour-enhanced funnel plot and use Egger's test and visual inspection to determine plot asymmetry, if there are ten or more studies for an outcome \[[@CR51]\].

All meta-analyses will be conducted using Review Manager software version 5.3 (RevMan 5.3) \[[@CR52]\] while Comprehensive Meta-Analysis software version 3 (CMA 3.0) will be used for Egger's test \[[@CR53]\]. When meta-analysis is not appropriate, a table for summary of findings will be created using GRADEpro software and a narrative summary will be reported. The results of this systematic review will be presented according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR43], [@CR44]\]. When amendments of the protocol are needed, we will document the date and the rationale for these changes.

Discussion {#Sec15}
==========

As the number of SCBT increased over time, it has become apparent that the burden of surviving a brain tumor is significant \[[@CR4], [@CR6], [@CR12], [@CR13]\]. Obesity is a critical comorbidity to address in survivors, as it drives the risk of cardiovascular diseases, type 2 diabetes, metabolic syndrome, and hypertension \[[@CR7], [@CR8], [@CR17]--[@CR19]\]. This reduces the quality of life and lifespan of the survivors and increases healthcare system utilization.

In order to improve health outcomes in SCBT, it is important to develop evidence-based interventions to treat and prevent obesity and its cardiometabolic comorbidities.

The findings from this systematic review will have important implications for SCBT, as it will provide insights into the current best form of obesity intervention for these patients. The review will also define gaps in knowledge and help improve the quality of life and lifespan of SCBT by guiding the design of new interventions to target obesity and its cardiometabolic comorbidities.
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